Rationale and Objectives Relapse to alcohol use during abstinence or maladaptive eating habits during dieting is often provoked by stress. The anxiogenic drug yohimbine, which causes stress-like responses in humans and nonhumans, reliably reinstates alcohol and food seeking in a rat relapse model. Yohimibine is a prototypical alpha-2 adrenoceptor antagonist, but results from studies on noradrenaline"s role in yohimbine-induced reinstatement of drug and food seeking are inconclusive. Here, we further addressed this issue by studying the effect of the alpha-1 adrenoceptor antagonist prazosin and the alpha-2 adrenoceptor agonist guanfacine on yohimbine-induced reinstatement. Methods In exp. 1, we trained rats to self-administer alcohol (12% w/v, 1 h/day), and after extinction of alcohol-reinforced lever pressing, we tested prazosin"s (0.5, 1.0, and 2.0 mg/kg, i.p.) or guanfacine"s (0.125, 0.25, and 0.5 mg/kg, i.p.) effect on yohimbine (1.25 mg/kg, i.p.)-induced reinstatement; we also examined prazosin"s effect on intermittent-footshock-stress-induced reinstatement. In exp. 2, we trained food-restricted rats to selfadminister 45 mg food pellets and first examined prazosin"s or guanfacine"s effects on food-reinforced responding, and then, after extinction of lever presses, on yohimbineinduced reinstatement. Results Prazosin (0.5-2.0 mg/kg) blocked yohimbineinduced reinstatement of food and alcohol seeking, as well as footshock-induced reinstatement of alcohol seeking. Guanfacine attenuated yohimbine-induced reinstatement of alcohol seeking at the highest dose (0.5 mg/kg), but its effect on yohimbine-induced reinstatement of food seeking was not significant. Neither prazosin nor guanfacine affected high-rate food-reinforced responding. Conclusions Results demonstrate an important role of postsynaptic alpha-1 adrenoceptors in stress-induced reinstatement of alcohol and food seeking.
relapse to alcohol use or maladaptive eating habits during dieting are unknown.
Over the last decade, investigators have used a rat reinstatement model (Shaham et al. 2003) to study neuronal mechanisms of stress-induced relapse to alcohol seeking (Le and Shaham 2002; Weiss et al. 2001) . Since 2006, the reinstatement model has also been used to study mechanisms of stress-induced relapse to palatable food seeking (Ghitza et al. 2006; Nair et al. 2009a) . In earlier studies with alcohol-experienced rats, the main stressor used to reinstate alcohol seeking was intermittent footshock (Le et al. 1999 (Le et al. , 1998 Liu and Weiss 2002) . More recently, we and others have been using the pharmacological stressor yohimbine, which potently reinstates both alcohol and palatable food seeking (Ghitza et al. 2006; Le et al. 2005; Nair et al. 2009b; Richards et al. 2008) . Yohimbine is a prototypical alpha-2 adrenoceptor antagonist that increases noradrenaline cell firing and noradrenaline release in terminal areas (Abercrombie et al. 1988; Aghajanian and VanderMaelen 1982) and induces anxiety-like responses in both humans and non-humans (Bremner et al. 1996a, b; Holmberg and Gershon 1961; Lang and Gershon 1963) . Yohimbine"s effect on reinstatement of both alcohol and food seeking is likely due to the induction of a stress-like state because this effect is blocked by systemic injections of antalarmin, a corticotropin-releasing factor (CRF) 1 receptor antagonist (Ghitza et al. 2006; Marinelli et al. 2007 ). The stress neurohormone CRF, via its action on extrahypothalamic brain sites, mediates footshock-stress-induced reinstatement of drug and alcohol seeking (Shaham et al. 2000a; Shalev et al. 2010 ).
As mentioned above, yohimbine is a prototypical alpha-2 adrenoceptor antagonist; thus, it would be expected that activation of central noradrenergic systems mediates its potent effect on reinstatement of drug and food seeking. However, results from studies on the role of central noradrenergic systems in yohimbine-induced reinstatement are mixed. While the alpha-2 adrenoceptor agonist clonidine attenuates yohimbine-induced reinstatement of alcohol seeking in rats and cocaine seeking in monkeys (Le et al. 2009; Lee et al. 2004) , clonidine has no effect on yohimbine-induced reinstatement of cocaine or food seeking in rats or yohimbine-induced reinstatement of cocaineconditioned place preference (CPP) in mice (Brown et al. 2009; Mantsch et al. 2010; Nair et al. 2009a ). Additionally, 6-hydroxydopamine lesions of the ventral or dorsal noradrenergic bundles have no effect on yohimbine-induced reinstatement of alcohol seeking (Le et al. 2009 ). Additionally, yohimbine"s effect on reinstatement of food or alcohol seeking is not mimicked by RS79948, a selective alpha-2 adrenoceptor antagonist (Le et al. 2009; Nair et al. 2009b) . In contrast, in monkeys, yohimbine"s effect on reinstatement is mimicked by RS79948 (Lee et al. 2004) , and in mice this effect of yohimbine is mimicked by another selective alpha-2 adrenoceptor antagonist, BRL44408 (Mantsch et al. 2010) . These authors also reported that yohimbine-induced reinstatement of cocaine CPP in mice is attenuated by the beta adrenoceptor antagonist, propranolol (Mantsch et al. 2010) .
Here, we further characterized the role of noradrenaline in yohimbine-induced reinstatement of alcohol and food seeking by using the alpha-1 adrenoceptor antagonist prazosin (Cohen 1970 ) and the alpha-2 adrenoceptor agonist guanfacine (Scholtysik et al. 1975) . We studied prazosin because this drug decreases stress responses in laboratory animals (Handley and Mithani 1984; Manion et al. 2007 ). Additionally, Rasmussen et al. (2009) showed that prazosin decreases alcohol intake (two-bottle choice) in alcohol-preferring P rats, and Walker et al. (2008) showed that the drug decreases dependence-induced increases in operant alcohol self-administration in Wistar rats. Furthermore, to our knowledge, the effect of alpha-1 adrenoceptor antagonists on footshock stress-or yohimbine-induced reinstatement of alcohol seeking has not been determined. We studied guanfacine because the drug decreases excitatory postsynaptic neurotransmission in the medial prefrontal cortex (mPFC) (Ji et al. 2008 ) and bed nucleus of the stria terminalis (BNST) (Shields et al. 2009 ); these brain areas were recently implicated in yohimbine-induced reinstatement of drug and food seeking (Buffalari and See 2010; Nair et al. 2011) . Additionally, guanfacine was recently approved for the treatment of attention deficit hyperactive disorder (ADHD) (Sallee and Eaton 2010) . Thus, positive findings from a rat relapse model could prompt translational studies on the drug"s efficacy for relapse prevention in humans.
Materials and methods
The experimental procedures followed the "Principles of laboratory animal care" (NIH publication no. 85-23, 1996) and were approved by the local animal care and use committee.
Subjects and apparatus
Exp. 1: alcohol Forty-one male Wistar rats (Charles River; St-Constant, QC, Canada) weighing 150-200 g (age, 7-8 weeks) at the start of the experiment were used. The rats were individually housed under a 12:12-h light-dark cycle (light on at 7:00 a.m. to 7:00 p.m.). Food and water were freely available in the home cage during all phases of the experiments, and the temperature was maintained at 21± 1°C. The self-administration chambers were constructed locally and were equipped with two levers, symmetrically centered on a side panel. During the selfadministration sessions, responding on one lever (an active lever) activated an infusion pump (Razel Sci.; Stamford, CT), while responding on the other lever (an inactive lever) was recorded, but did not activate the pump. Activation of the infusion pump resulted in the delivery of 0.19 ml of alcohol into a drinking receptacle located between the two levers and initiated a 5-s timeout period. The grids of the self-administration chambers were connected to scrambled shockers (Med Associates; Georgia, VT).
Exp. 2: food Twelve male Long-Evans rats (Charles River; Raleigh, NC) weighing 350-450 g (age, 11-14 weeks) at the start of the experiment were used. The rats were housed individually in the animal facility under a reverse 12-h: 12-h light-dark cycle (lights off at 8 a.m.). All rats were kept on a restricted diet of 16 g/day of Purina rat chow (about 60-65% of their daily food intake) during the training phase and 20-22 g/day during the extinction and reinstatement test phases to maintain stable body weight. The experiments were conducted in standard selfadministration chambers (Med Associates; Georgia, VT). Each chamber had two levers 9 cm above the floor, but only one lever ("active", retractable lever) activated the pellet dispenser, which delivered 45-mg food pellets containing 12.7% fat, 66.7% carbohydrate and 20.6% protein (catalogue # 1811155, TestDiet; Richmond, IN). This particular pellet was chosen based on pellet preference tests in food-restricted rats, using six pellet types (obtained from TestDiet and Bioserv) with different compositions of fat (0% to 35%) and carbohydrate (45% to 91%; sugar pellets) at different flavors (no flavor, banana, chocolate, grape). The chambers were also equipped with photobeams to record head entries into the food receptacles.
Drugs
An alcohol solution was prepared by diluting 95% ethanol (Commercial Alcohols Inc.; Tiverton, ON, Canada) in tap water. Guanfacine HCl (N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride) was dissolved in saline, and prazosin HCl (1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride) and yohimbine HCl (17-hydroxyyohimban-16-carboxylic acid methyl ester hydrochloride) were dissolved in distilled water; all drugs were obtained from Sigma (St. Louis, MO). In exp. 1, guanfacine (0, 0.125, 0.25, and 0.5 mg/kg, i.p.), prazosin (0, 0.5, 1.0, and 2.0 mg/kg, i.p.) and yohimbine (0, 1.25 mg/kg, i.p.) were injected at a volume of 1 ml/kg, except the high prazosin dose that was injected at 2 ml/kg. In exp. 2, the injection volume for yohimbine was 0.5 ml/kg and 2 ml/kg for prazosin and guanfacine. The yohimbine dose was based on our previous studies (Ghitza et al. 2006; Le et al. 2009 Le et al. , 2005 Shepard et al. 2004 ). The doses of prazosin and guanfacine were based on previous reports (Dekeyne and Millan 2006; Forget et al. 2010; Handley and Mithani 1984; Manion et al. 2007; Rasmussen et al. 2009; Sagvolden 2006; Walker et al. 2008 ).
Procedures
Exp 1: alcohol Rats were trained to self-administer alcohol as described previously (Le et al. 1998 (Le et al. , 2005 . Briefly, naive rats were initially provided with access to alcohol solutions and tap water for 30 min/day in novel drinking cages (30×18× 18 cm) containing Richter tubes. Alcohol solutions were provided in increasing concentrations: 3% (w/v) for the first 5 days, 6% for the next 5 days and 12%) for the next 10 days. Subsequently, operant self-administration of alcohol (12%) was initiated in 1-h daily sessions on a fixed ratio-one (FR-1) 5-s timeout reinforcement schedule for at least 5 days (1 h/day). During the timeout, the house light was turned off; a key light over the active lever was turned on, and white noise was emitted by a speaker. The beginning of the sessions was signalled by the illumination of a house light located at the top of the self-administration chamber; at the end of the session, the house light was turned off. The requirement for alcohol delivery was then increased to an FR-2 reinforcement schedule for 5 days. Subsequently, the schedule requirement was increased to an FR-3 schedule for at least 6 days, until the rats demonstrated 3 days of stable alcohol-taking behaviour (variability of less than 20% of the mean). When alcohol was left in the drinking receptacle after a self-administration session, it was measured, and the volume was taken into account for intake calculation.
Exp. 1a: effect of prazosin or guanfacine on yohimbineinduced reinstatement of alcohol seeking Forty-one rats were trained to self-administer alcohol as described above. The rats then received ten daily extinction sessions. These sessions were identical to the self-administration sessions, except that the infusion pumps used to deliver alcohol were inactivated. The extinction sessions continued until the rats reached an extinction criterion of fewer than 12 active lever presses/1 h during two consecutive days; during the last four extinction sessions, the rats received vehicle injections to habituate them to the injection procedure. Two groups of rats (n=9-10 per group), which were matched for alcohol intake and extinction responding, were assessed for the effect of prazosin on yohimbine-induced reinstatement, using a mixed design that included the between-subjects factor of yohimbine dose (0, 1.25 mg/kg) and the withinsubjects factor of prazosin dose (0, 0.5, 1.0, and 2.0 mg/kg). Two other groups of rats (n=10-11 per group) were assessed for the effect of guanfacine on yohimbine-induced reinstatement, using a mixed design that included the between-subjects factor of yohimbine dose (0, 1.25 mg/kg) and the within-subjects factor of guanfacine dose (0, 0.125, 0.25, and 0.5 mg/kg). On the test days, each rat was injected with the vehicle or one of the prazosin/guanfacine doses, and 15 min later, with the vehicle or yohimbine. Forty-five minutes after the second injection, the rats were placed in the self-administration chambers for the 1-h reinstatement test sessions. The order of the injections of the different prazosin/ guanfacine doses was counterbalanced, and tests were performed every other day, with regular extinction sessions on the intervening days.
Exp. 1b: effect of prazosin on footshock-induced reinstatement of alcohol seeking Twenty rats from exp. 1a were used after the completion of yohimbine testing. They received four additional daily extinction sessions. The effect of prazosin on intermittent footshock-induced reinstatement was assessed using a mixed design that included the within-subjects factor of footshock (no shock, shock; n =10 per condition) and the between-subjects factor of prazosin dose (0 and 0.5 mg/kg). Each rat was injected with the vehicle or prazosin 40 min before two daily 1-h test sessions; the first day was the baseline (no shock) session, and the second day was the footshock test session. The 5-min intermittent footshock stress was administered just prior to the start of the 1-h test session. The shock parameters of 0.8 mA, 0.5 s ON, a mean OFF period of 40 s, and a range of 10-70 s between each shock delivery were based on our previous work (Le et al. 1998; Shaham and Stewart 1995) .
Exp. 2: Food
Exp. 2a: Effect of prazosin or guanfacine on foodreinforced responding The rats were first given 3-h daily sessions of "autoshaping" for 2 days during which pellets were administered non-contingently every 5 min into a receptacle located near the active lever. Pellet delivery was accompanied by a compound 5-s tone (2,900 Hz, 20 dB above background)-light (a 7.5-W white light located above the active lever) cue. Subsequently, the rats were trained to lever-press for the pellets on an FR1, 20-s timeout reinforcement schedule for 3 h/day for 5 days. At the start of the session, the red house light was turned on, and the active lever was extended. Following each pellet delivery, the compound tone-light cue (termed "cue" herein) was turned on for 5 s. During the training days, regular food (16 g Purina rat chow) was given after the daily session (approximately 4 h into the dark cycle).
After the initial 5-day training, we used a within-subjects design to assess the effect of prazosin (0, 1.0, and 2.0 mg/kg, n=6) or guanfacine (0, 0.25, and 0.5 mg/kg, n=6) on highrate food-reinforced responding. The drugs or their vehicle were injected 60 min before the test sessions, which were performed every other day. The order of the different doses was counterbalanced, and regular training days were performed in the intervening days.
Exp. 2b: Effect of prazosin or guanfacine on yohimbineinduced reinstatement of food seeking After the completion of exp. 2a, the rats" active-lever responding was extinguished over 12 daily 3-h sessions during which lever presses led to tone-light cue presentations but not food. The rats (n=12) underwent six test sessions every other day, during which they were injected with yohimbine (1.25 mg/ kg) or distilled water and then injected with the vehicles of prazosin or guanfacine (n = 6 per vehicle condition), prazosin (2.0 mg/kg, n=12), or guanfacine (0.5 mg/kg, n =12). The order of test sessions was counterbalanced, and the rats were given regular extinction sessions on the intervening days. Prazosin, guanfacine, or their vehicles were injected 60 min before the start of the test sessions, and yohimbine was injected 15 min after the prazosin/ guanfacine injections.
Statistical analysis
The statistical analyses were performed separately on previously active and inactive lever presses during the reinstatement tests. The food-reinforced responding data were analysed for total pellet intake, lever presses during the 20-s timeouts after each pellet delivery and number of magazine entries (photobeam counts). Data were analysed with ANOVAs, and significant interactions (p values<0.05) were followed by a Newman-Keuls post-hoc test (exp. 1) or a Fisher PLSD post-hoc test (exp. 2).
Results

Exp. 1: alcohol
The mean±SEM number of alcohol deliveries (1 h), alcohol intake (grams per kilogram), and active and inactive lever presses (1 h) on the last training day under the FR-3 reinforcement schedule was 25.57 ± 1.24, 1.49 ± 0.07, 85.44±4.61, and 0.61±0.24, respectively (total n=41). The mean±SEM number of previously active and inactive lever presses on the first and last extinction sessions (prior to the start of the reinstatement tests) was 72.71± 5.95, 0.66± 0.24, 9.02± 0.88, and 0.51± 0.18, respectively (total n =41).
Exp. 1a: Effect of prazosin or guanfacine on yohimbine-induced reinstatement of alcohol seeking Both prazosin and guanfacine decreased yohimbineinduced reinstatement of alcohol seeking without affecting baseline extinction responding (Fig. 1a) . The statistical analyses included the within-subjects factor of prazosin dose (0, 0.5, 1.0, 2.0 mg/kg) or guanfacine dose (0, 0.1, 0.25, 0.5 mg/kg) and the between-subjects factor of yohimbine dose (0, 1.25 mg/kg). The analyses of active lever presses showed significant prazosin dose×yohimbine dose [F(3,53) F(3,56) =3.2, p<0.05] interaction effects. The analyses of the inactive lever data did not show significant effects, and inactive lever presses were very low during testing (means of less than 5 presses per 1 h, data not shown). Post-hoc differences are indicated in Fig. 1a .
Exp. 1b: Effect of prazosin on footshock-induced reinstatement of alcohol seeking Prazosin decreased intermittent footshock-induced reinstatement of alcohol seeking without affecting baseline extinction responding (Fig. 1b) . The statistical analyses included the between-subjects factor of prazosin dose (0, 0.5 mg/kg) and the within-subjects factor of footshock (no shock, shock). The analysis of active lever presses showed a significant prazosin dose×yohimbine dose interaction effect [F(1,18)=5.3, p< 0.05]. The analyses of inactive lever data did not show any significant effects, and inactive lever presses were very low during testing (means of less than 4 presses per 1 h, data not shown). Post-hoc differences are indicated in Fig. 1b .
Exp. 2: food
The mean±SEM number of pellet deliveries (3 h), timeout lever presses, inactive lever presses, and magazine entries on the last training day under an FR-1, 20-s timeout reinforcement schedule was 239±26, 553±116, 1.0±0.6, and 670±114, respectively (total n=12). The mean±SEM number of previously active lever presses (3 h), inactive lever presses, and magazine entries on the first extinction session (prior to the start of the reinstatement tests) was 395±59, 6.0±2.7, and 213±42, respectively (total n=12). The mean±SEM number of previously active lever presses (3 h), inactive lever presses, and magazine entries on the 12th and last extinction session (prior to the start of the reinstatement tests) was 12±2, 0.8±0.4, and 28±6, respectively (total n=12).
Exp. 2a: Effect of prazosin and guanfacine on food-reinforced responding
Neither prazosin nor guanfacine had an effect on pellet deliveries (3 h), timeout lever presses, and magazine entries (Fig. 2 ). These drugs also had no effect on inactive lever presses, which were very low during the dose-response determination (less than 3 presses per 3 h, data not shown).
Exp. 2b: Effect of prazosin or guanfacine on yohimbine-induced reinstatement of food seeking
Prazosin decreased yohimbine-induced reinstatement of both active lever presses and magazine entries, while guanfacine In a, rats were injected with prazosin, guanfacine, or their vehicle 60 min before the test sessions and then were injected with yohimbine or its vehicle 45 min before these sessions. In b, rats were injected with prazosin 40min before the test sessions, and intermittent footshock (5 min) was given (or not given) just prior to the start of the test session. Asterisk different from the appropriate prazosin or the guanfacine vehicle condition, p<0.05 (n=9-11 per drug condition) had a variable effect on this reinstatement (see below); neither prazosin nor guanfacine affected baseline extinction responding (Fig. 3a,b) . The statistical analyses separately compared the vehicle condition (combining the 6 rats given the prazosin vehicle and the 6 rats that received the guanfacine vehicle together with yohimbine or its vehicle, total n=12) with the same 12 rats that received prazosin or guanfacine together with yohimbine or its vehicle (a total of 6 tests). The two analyses included the within-subjects factors of prazosin dose (0, 2.0 mg/kg) or guanfacine dose (0, 0.5 mg/kg) and yohimbine dose (0, 1.25 mg/kg).
Prazosin The analysis of active lever presses and food cup entries showed significant prazosin dose×yohimbine dose interaction effects [F(1,11)=18.1, p<0.01 and F(1,11)=5.4, p<0.05, respectively]. Prazosin also reduced the increase in inactive lever presses after yohimbine injections (mean± SEM presses per 3 h of 14.5±5.5, and 0.8±0.2 in the vehicle+yohimbine and prazosin+yohimbine conditions, respectively, p<0.05). However, the result of a follow-up change-score analysis (active lever presses minus inactive lever presses) was similar to that of the active lever analysis (a significant prazosin dose×yohimbine dose interaction effect, [F(1,11)=21.3, p<0.01]). Post-hoc differences are indicated in Fig. 3b .
Guanfacine Initial analysis showed a main effect of yohimbine dose [F(1,11)=19.4, p<0.01] but not of guanfacine dose or guanfacine dose×yohimbine dose. However, we observed large individual differences in the response to guanfacine, with five rats showing no change or increased yohimbine-induced reinstatement; while in seven other rats, guanfacine decreased yohimbine-induced reinstatement of lever presses [F(1,6)=28.2, p<0.01] but not food cup entries (p>0.1) (Fig. 3c) . There was no significant effect of guanfacine on inactive lever presses (data not shown).
Discussion
The main finding of our study is that the alpha-1 adrenoceptor antagonist prazosin blocked yohimbineinduced reinstatement of alcohol and food seeking, as well as intermittent footshock stress-induced reinstatement of alcohol seeking. We also found that the alpha-2 agonist guanfacine attenuated yohimbine-induced reinstatement of alcohol seeking. In contrast, the effect of the highest dose of guanfacine on yohimbine-induced reinstatement of food seeking was inconsistent. Below, we first discuss methodological issues related to data interpretation and then discuss these data in reference to the role of central noradrenergic systems in stress-induced reinstatement.
Methodological considerations
One issue to consider is that the effects of prazosin or guanfacine on yohimbine-and footshock-induced reinstatement are due to non-specific disruption of motor activity. At issue here is that, at high doses, both alpha-1 and alpha-2 adrenoceptor agonists cause sedation, which would interfere with lever presses (Drew et al. 1979; Munzar and Goldberg 1999) . This possibility is unlikely because at the dose range used here, neither prazosin nor guanfacine decreased baseline extinction responding (Figs. 1, 2, and 3) and, more importantly, had no effect on high-rate foodreinforced responding (Fig. 2) . Another issue to consider is that in exp. 2, yohimbine also increased inactive lever presses, suggesting a potential non-selective effect of yohimbine on motor performance. However, we suspect that this effect of yohimbine likely reflects response generalization rather than a non-selective effect on lever responding because yohimbine had no effect on inactive lever responding in exp. 1. Furthermore, in our previous studies on yohimbine-induced reinstatement of food seeking, the drug"s effect on inactive lever responding was inconsistent (Ghitza et al. 2006 (Ghitza et al. , 2007 Nair et al. 2009a Nair et al. , 2008 Nair et al. , 2011 . Additionally and perhaps more importantly, yohimbine"s increases in active lever responding in exp. 2 were associated with increases in magazine entries (Fig. 3) , which indicates that yohimbine indeed caused "food seeking" rather than non-specific increase in activity.
An unexpected finding in our study was the different effects of guanfacine on yohimbine-induced reinstatement in alcohol-trained rats versus food-trained rats. Several procedural differences in the way the experiments were 2), and the use of different rewards (alcohol versus food). It is currently unknown which of these factors might be involved in guanfacine's selective effect on yohimbine-induced reinstatement of alcohol but not food seeking. We suspect that the critical factor might be the reward type because the present results extend those from our previous studies demonstrating that the alpha-2 adrenoceptor agonist clonidine decreased yohimbine-induced reinstatement of alcohol seeking but not food seeking (Le et al. 2009; Nair et al. 2009a ). These present and previous findings raise the possibility that the neuronal mechanisms of yohimbine-induced reinstatement of alcohol seeking and yohimbine-induced reinstatement of palatable food seeking during dieting are not identical. Support for this notion is the finding that the hypocretin 1 receptor antagonist SB 334,847 decreased yohimbine-induced reinstatement of alcohol seeking but not food seeking (Nair et al. 2008; Richards et al. 2008 ). However, this interpretation of the present data should be made with caution because we only tested one guanfacine dose against yohimbine-induced reinstatement in foodtrained rats. Thus, it is possible that a higher guanfacine dose would result in a higher proportion of rats that are sensitive to guanfacine"s effect on yohimbine-induced reinstatement.
A pharmacological issue to consider is the receptor type(s) through which prazosin or guanfacine acts to decrease yohimbine-induced and footshock-induced reinstatement. While we interpret these data to suggest a role of alpha-1 and alpha-2 adrenoceptors in this reinstatement, other receptor types might be involved. Specifically, while prazosin is often used as an alpha-1 adrenoceptor antagonist, it also binds with modest affinity to alpha-2 adrenoceptors (Ki = 109-219) (Boyajian and Leslie 1987) . However, prazosin"s affinity to the alpha-1 adrenoceptor is significantly higher (Ki=0.12-0.31) (Doxey et al. 1984; Millan et al. 2000) , and its effect on yohimbine-induced reinstatement Fig. 3 Exp. 2: food: effect of prazosin or guanfacine on yohimbineinduced reinstatement. Data are mean±SEM presses on the previously active lever and mean±SEM food cup entries. a, b Effect of prazosin or guanfacine on yohimbine-induced reinstatement (n=12 per drug condition, within-subjects design). c Effect of guanfacine on yohimbine-induced reinstatement in groups of rats that either decreased (n=7) or did not decrease (n=5) yohimbine-induced reinstatement after guanfacine injections. The rats were injected with prazosin, guanfacine, or their vehicles 60 min before the test sessions and then were injected with yohimbine or its vehicle 45 min before these sessions. Asterisk different from the appropriate prazosin or the guanfacine vehicle condition, p<0.05 was not reproduced in food-trained rats by guanfacine. Thus, the most parsimonious pharmacological interpretation of our data is that prazosin"s effect on stress-induced reinstatement is due to blockade of alpha-1 adrenoceptors. As for guanfacine, the drug also binds at a moderate degree to the 5-HT1a receptor, but its affinity to the alpha-2 adrenoceptor agonist is significantly higher (Newman-Tancredi et al. 1998) . Thus, it is likely that, at the dose range used here, the effect of guanfacine on yohimbine-induced reinstatement of alcohol seeking is due to its actions on alpha-2 adrenoceptors. Finally, our data suggest that targeting alpha-1 adrenoceptors with prazosin is a more effective way to reduce yohimbine-induced reinstatement than targeting the alpha-2 adrenoceptors (the presumed receptor target of yohimbine) with guanfacine. However, this conclusion should be made with caution because it is possible that guanfacine doses that are higher than the ones we tested in our study would decrease yohimbine-induced reinstatement more effectively.
Role of noradrenaline in stress-induced reinstatement of alcohol and food seeking
The robust effect of prazosin on footshock-induced reinstatement of alcohol seeking in the present study extends previous work on the role of central noradrenaline systems in footshock-stress-induced reinstatement of drug seeking (Bossert et al. 2005; Brown et al. 2009 ) and further identifies a potential postsynaptic adrenoceptor (alpha-1) that mediates this effect. In the present study, we only injected prazosin systemically, and thus, its effect on footshock-induced (or yohimbine-induced) reinstatement might be due to its peripheral effects. However, this possibility is relatively unlikely because results from previous studies using intracranial injection and lesion methods and peripheral injections of non-lipophilic drugs demonstrate that central but not peripheral noradrenaline systems mediate the effect of intermittent footshock stress on reinstatement of drug seeking (Erb et al. 2000; Leri et al. 2002; Shaham et al. 2000b; Wang et al. 2001; Yamada and Bruijnzeel 2010) .
The inhibitory effect of prazosin or guanfacine on yohimbine-induced reinstatement of alcohol seeking in the present results also supports a role for central noradrenergic systems in yohimbine-induced reinstatement of alcohol seeking. However, while these data are in agreement with our previous finding that yohimbine-induced reinstatement is inhibited by clonidine, they are not in agreement with our findings that lesions of the dorsal or ventral noradrenergic bundle have no effect on yohimbine-induced reinstatement (Le et al. 2009 ). The dorsal noradrenergic bundle comprises locus coeruleus neurons that project to many forebrain areas and provide the sole noradrenergic input to cortical areas such as the hippocampus and the frontal cortex (Foote et al. 1983; Moore and Bloom 1979) . The ventral noradrenergic bundle is composed of neurons from the lateral tegmental nuclei that innervate a smaller number of forebrain areas (most of which are also innervated by locus coeruleus neurons), and its major projection areas include the hypothalamus, central amygdala, septum, nucleus accumbens, and BNST (Aston-Jones et al. 1999; Fritschy and Grzanna 1991; Pacak et al. 1998) .
The reasons for the discrepant results between the effect of systemic injections of adrenoceptor drugs and central noradrenaline lesions are unknown. One possibility is that this discrepancy reflects peripheral effects of the pharmacological agents. However, since results from recent studies using reversible inactivation methods and intracranial drug injections indicate central actions for yohimbine"s effect on reinstatement of drug and food seeking (Buffalari and See 2010; Nair et al. 2011 ), this possibility is unlikely. We speculate that the discrepancy between systemic drug injections and central noradrenergic lesions might reflect the limitation of the 6-OHDA lesion methodology used in our previous study to lesion the dorsal and ventral noradrenergic bundles (Le et al. 2009 ). In particular, even highly effective 6-OHDA monoamine lesions (90-95%) do not decrease extracellular concentration of the monoamines, often do not decrease behavioral responses to systemic drug injections, and may lead to postsynaptic receptor supersensitivity (Kostrzewa et al. 2003; Pappas and Ings 1987; Robinson and Whishaw 1988; Tassin et al. 1986) .
A question that we did not address in our study is the role of postsynaptic beta-adrenoceptors in yohimbineinduced reinstatement of alcohol and food seeking. Based on some evidence, we suspect that activation of beta adrenoceptors also contributes to this reinstatement. Thus, systemic injections of the beta adrenoceptor antagonist propranolol decreased yohimbine-induced reinstatement of cocaine CPP (Mantsch et al. 2010) . Additionally, propranolol injections attenuated the effect of yohimbine on the induction of Fos (the protein product of the immediate early gene c-fos; Curran and Morgan 1995) in the mPFC (Bing et al. 1992 ), a brain area recently implicated in yohimbineinduced reinstatement of food seeking (Nair et al. 2011) .
Finally, we previously found that systemic injections of the CRF1 receptor antagonists CP-154,526 and antalarmin respectively decreased intermittent footshock-and yohimbine-induced reinstatement of alcohol seeking (Le et al. 2000; Marinelli et al. 2007 ). We also found that antalarmin decreased yohimbine-induced reinstatement of food seeking (Ghitza et al. 2006) . Additionally, we found that both yohimbine injections and intermittent footshock exposure increased CRF mRNA expression in the BNST (Funk et al. 2006 ), a brain area in which blockade of CRF receptors decreased footshock-induced reinstatement of cocaine seeking (Erb and Stewart 1999) . Recently, it was reported that reversible inactivation of the BNST with a mixture of the GABAa and GABAb agonists muscimol and baclofen decreased yohimbine-induced reinstatement of cocaine seeking (Buffalari and See 2010) . Together, these observations, our present and previous data, as well as results from other studies (Brown et al. 2009; Leri et al. 2002; Shalev et al. 2010) , suggest that an interaction between CRF and noradrenaline in the BNST plays an important role in both yohimbine-and intermittent footshock-induced reinstatement of alcohol and food seeking.
Concluding remarks and implications for treatment
Prazosin and guanfacine have been used in the past for the treatment of PTSD and ADHD, respectively (Byers et al. 2010; Sallee and Eaton 2010) . Guanfacine was also recently approved by the FDA for the treatment of ADHD. Here, we showed that both guanfacine and prazosin blocked stress-induced reinstatement of alcohol seeking. Thus, to the extent that the reinstatement procedure provides a valid animal model of craving and relapse , we propose that both prazosin and guanfacine, which are both safe and well tolerated in humans, should be tested in clinical studies in alcoholics for their effects on stress-induced craving in the laboratory and stress-induced relapse in the alcoholic home environment. We also hope that our data will lead to human studies on prazosin"s effect on stress-induced food craving and relapse to maladaptive eating habits during dieting.
